2,222 press releases in English indexed under biotech & pharma.
The Spreading Ebola Epidemic as well as Mpox Endemic in Africa Disproportionately Impact Children; The Measles Outbreaks Primarily Impact Children
Eligible investors can now participate in the development of GOA26, designed to rapidly lower blood alcohol concentration and sequester acetaldehyde Eligible investors can now participate in the development of GOA26, designed to rapidly lower blood alcohol concentration and sequester acetaldehyde
Favorable interim safety and tolerability profile observed across single and multiple ascending dose cohorts in healthy volunteers Favorable immunogenicity, with single digit percentage Anti-drug Antibody (ADA) incidence at predicted therapeutic dose levels Extended pharmacokinetics and target suppression support potentia
John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 toward potential partnerships John Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic Colorectal Cancer (mCRC) and PDS0101 toward potential partnerships
TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 20, 2026 -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection and ophthalmologic innovations, today announced a strategic collaboration with EG BioMed Co., Ltd., a Taiwan registered company and an affiliate of YD Bio (“EG BioMed”), and digital health provider JoiiUp. The partnership integrates an AI Cancer Risk Assessment (the “Assessment”), jointly developed by YD Bio and EG BioMed, into JoiiUp’s JoiiSports app, expanding access to personalized health insights for corporate wellness programs and healthcare institutions.
Multi-year, purpose-driven campaign connects McLaren's on-track performance with support for global patient advocacy organizations serving people...
Expands Kane Biotech’s commercial footprint and access to the revyve® product line across Canada
Laser Photonics Corporation (NASDAQ:LASE), an emerging directed energy and laser technology platform developing applications for defense, semiconductor, pharmaceutical and industrial markets (the "Company"), today announced the appointment of Tim Peterman as Chief Financial Officer. Mr. Peterman's appointment, together with the Company's recent engagements of Sheppard, Mullin, Richter & Hampton LLP ("Sheppard") as ou
RALEIGH, N.C., Oct. 20, 2026 -- Slate Medicines, Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and potentially improve outcomes for people with migraine and other headache disorders, today announced the appointment of Stephen K. Brannan, MD, and John D. Young to the company’s Board of Directors. Dr. Brannan brings more than 25 years of clinical development experience in CNS disorders and most recently served as the Chief Medical Officer of Karuna Therapeutics. Mr. Young brings more than 35 years of biopharmaceutical industry experience, including serving as a member of the Executive Leadership Team at Pfizer, most recently as Group President and Chief Business Officer.
Favorable tolerability profile and oral administration underscore the potential of OD-001 as a monotherapy and backbone for combination regimens in IBD
Primary endpoint met, with 85% free of respiratory failure at Day 7 vs. 33.3% with placebo (p<0.0001) 72% reduction in risk of death at day-28 (HR 0.28; p=0.033), with benefit sustained at six months Hospital stay cut from 14.4 to 6.5 days (p=0.0001) Well tolerated; no treatment-related serious adverse events Nano24 plans
– Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of Compassionate Use Treatment in a Pediatric Patient – Patient’s Skin Improved from Severe to Clear with Complete Elimination of Pruritus (itch) – After 21 Months of Treatment with QRX003, Patient’s Skin Remains Fully … Continue reading "Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy"